LIVE
BREAKING LIVE

The news moving markets, right now

From international newswires in real time. For every story the News Impact AI agent estimates the market impact and flags the assets to watch, with the story’s impact on each: positive, negative or neutral.

STORIES TODAY
603
via seekingalpha.comBusiness & Companies

Beam Therapeutics (BEAM): initial Phase I/II BEAM-301 data in GSD type 1a

FROM THE WIRE · SEEKINGALPHA.COM

Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a October 27, 2026 8:00 AM EDTCompany...

Read at the source ↗
MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralEarly clinical data can move a biotech stock depending on the efficacy shown.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
  1. 01Beam Therapeutics presented initial Phase I/II data for BEAM-301.
  2. 02The study concerns glycogen storage disease type 1a.
  3. 03The presentation took place on October 27, 2026.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets

ALL BREAKING TODAY

Breaking live stories come from third-party newswires via feed; headline and summary belong to the stated source. Impact analysis: UCapital AI · News Impact.

AI use policy. UCapital AI supports the newsroom with news analysis, summaries, market reactions, translations and the generation of cards and charts. AI-generated or AI-assisted content is labelled in the byline (AI Desk, a named AI profile marked «AI», or joint byline) and is reviewed by editors before publication. News received via API feeds from third-party providers is attributed to the original source. AI can make mistakes: report any inaccuracies to the newsroom. Users’ personal data is not used to train the models.